

**Listing of the Claims:**

The following Listing of the Claims will replace all prior versions and all prior listings of the claims in the present application:

1-23. (Cancelled)

24. (Currently Amended) An isolated peptide of SEQ ID NO: 1, which binds to and stabilizes the native conformation of a ~~first~~ human p53 polypeptide, but not a denatured conformation of the first p53 polypeptide, ~~in which the peptide comprises a fragment of a second polypeptide, said fragment comprising 600 amino acids or fewer of said second polypeptide, and binds to a site of the first polypeptide which at least partially overlaps a functional site of the first polypeptide.~~

25. (Cancelled)

26. (Currently Amended) The peptide of Claim ~~25~~ 24, in which the p53 polypeptide ~~is p53~~ ~~which~~ comprises a mutation, selected from R175H, G245S, R248Q, R249S, R273H, R282W and I195T in which the mutation results in reversible denaturation of the polypeptide.

27. (Cancelled)

28. (Cancelled)

29. (Previously Presented) The peptide of claim 24 wherein said peptide is derivatised with a sugar, phosphate, amine, amide, sulphate, sulphide, biotin, a fluorophore or a chromophore.

30 - 38. (Cancelled)

39. (Previously Presented) The peptide of claim 24 in which the peptide is derivatised with a fluorophore.

40. (Previously Presented) The peptide of claim 39 wherein said fluorophore is fluorescein.

41 – 43. (Cancelled).

44. (Previously Presented) A pharmaceutical composition comprising a peptide according to claim 24, together with a pharmaceutically acceptable carrier, diluent or excipient.

45. (Previously Presented) A pharmaceutical composition comprising a peptide consisting of the sequence REDEDEIEW (SEQ ID NO: 1) together with a pharmaceutically acceptable carrier, diluent or excipient.

46 – 51. (Cancelled)

52. (New) An isolated peptide consisting of the sequence REDEDEIEW (SEQ ID NO: 1).